TWiV 1059: Keeping poliovirus out and Ebolavirus in
On this episode of TWiV we discuss unusual properties of monoclonal antibodies: one that that binds the receptor attachment site and blocks infection with all three poliovirus serotypes, and others th...
5 Nov 20231h 30min
TWiV 1058: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses health worker–perceived working conditions and symptoms of poor mental health, Mpox neutralizing antibodies at 6 months from mpox infection or MVA-...
4 Nov 202337min
TWiV 1057: CMV-based HIV vaccine with Klaus Früh
Klaus Früh visits the Incubator to discuss his career and his work on cytomegalovirus-vectored vaccines which are unique in their ability to persistently maintain an immune shield of effector memory T...
29 Okt 20231h 21min
TWiV 1056: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses health worker–perceived working conditions and symptoms of poor mental health, Mpox neutralizing antibodies at 6 months from mpox infection or MVA-...
28 Okt 202345min
TWiV 1055: Vermont viridae
Vincent travels to the University of Vermont to speak with Jason, Emily, Jessica, and Dimitry about their careers and their work on SARS-CoV-2, hantaviruses, poliovirus, influenza virus, and the invol...
22 Okt 20231h 41min
TWiV 1054: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses high Influenza incidence and disease severity among children and adolescents aged Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Be...
21 Okt 202342min
TWiV 1053: Bird flu in Baltimore
From the Centers for Excellence in Influenza Research and Response meeting in Baltimore, Vincent speaks with Ron Fouchier, Rafael Medina, and Louse Moncla about recent changes in the epidemiology of a...
15 Okt 202358min
TWiV 1052: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses disease severity of RSV compared with COVID-19 and Influenza among hospitalized adults aged ≥60 years, antiviral efficacy of Molnupiravir versus ri...
14 Okt 202342min
